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Summary: Patients with acute intermittent porphyria can be subdivided into three groups, according to the porpho-
bilinogen deaminase activity in their erythrocytes. The first group has lowered, the second overlapping and the
third normal porphobilinogen deaminase activity. Of 385 acute intermittent porphyria patients 5% had normal
porphobilinogen deaminase activity. Gene carriers of acute intermittent porphyria, which have normal porphobilino-
gen deaminase activity but display slight, moderate or high aberrations of excretion, are recognized by analysis of
urinary haem precursors and faecal poiphyrins. Six individuals suffering from acute intermittent porphyria were
detected in three families with normal porphobilinogen deaminase. There were no differences in the latent and
clinical phases of acute intermittent porphyria between patients with lowered and those with normal porphobilinogen
deaminase. One female with normal activity in erythrocytes, in which the porphyria disease process is triggered by
barbiturates and carbamazepin, is presented. After therapy with high doses of glucose and omission of inducing
agents, this woman was free of symptoms, and the excretion of different urinary porphyrin precursors and porphy-
rins decreased by between 65 and 93%.
Introduction
Acute intermittent porphyria is an inborn error of haem
metabolism and its inheritance is autosomal dominant.
More than 60 mutations causing acute intermittent por-
phyria, have been described so far (1, 2). These gene
defects cause an enzyme deficiency, which is charac-
terized by decreased activity of porphobilinogen deami-
nase3) in most tissues. The diminished porphobilinogen
deaminase activity and induction of hepatic 5-aminolae-
vulinate synthase by haem deficiency leads to the en-
hanced excretion of the haem precursors, 5-aminolae-
vulinic acid, porphobilinogen and porphyrins (3, 4). For
the diagnosis and detection of gene carriers, porphobili-
nogen deaminase is measured in erythrocytes. In hetero-
zygotes, enzyme activity is diminished to 40—60% of
the normal range (3, 4). A minor group of symptomatic
and asymptomatic acute intermittent porphyria patients
with typical diagnostic excretory patterns of porphyrin
precursors and porphyrins do not exhibit significant
variations of porphobilinogen deaminase activity in
erythrocytes (5, 6) compared with controls.
') Presented in part at the "International Conference Porphyrins,
Porphyria and Photodynamic Therapy", 22-26 November, 1993,
Melbourne, Australia, and at the "International Symposium on Por-
phyrias and Heme Related Disorders", Helsinki, Finland, June 28-
July 2, 1995.
2) This study was supported by the Hans-Fischer-Gesellschaft, Mu-
nich.
3) Enzymes:
5-Aminolaevulinate synthase (EC 2.3.1.37);
Porphobilinogen deaminase (EC 4.3.1.8).
The aim of the study was to detect and characterize the
acute intermittent porphyria patients with normal por-
phobilinogen deaminase activity in the erythrocytes in
our porphyrin consultation over a period of 20 years.
Studies were carried out on the families of three of
these patients.
Patients and Methods
Porphobilinogen deaminase activity was measured by the method
of Doss & von Tiepermann (7) and defined as nmol uroporphyrin
per litre erythrocytes per second formed from exogenous porpho-
bilinogen. The enzyme activity was analysed in 385 patients. Diag-
nosis of acute intermittent porphyria was established by the charac-
teristic excretion of haem precursors in urine and faeces. 5-Amino-
laevulinic acid and porphobilinogen were determined by ion ex-
change chromatography. Porphyrins were analysed spectro-
photometrically as methyl esters after separation by high perfor-
mance thin layer chromatography (8). The patients suffered from
a complex abdominal and neurological syndrome.
Results
Heterogeneity of acute in termi t tent porphyria
The reference value for porphobilinogen deaminase ac-
tivity, as determined by the method used, is 18 ± 4
nkat/1 (je ± SD, n = 274, CV = 22%). We investigated
385 patients (male : female = 1 : 2.2) with acute in-
termittent porphyria. Eightyseven percent of these per-
sons (n = 334) showed a lowered activity of porphobili-
nogen deaminase, (29—71%) compared with the control
group. Nineteen patients (5%) had normal porphobilino-
gen deaminase activity (85-110%) and 8% (n = 32) ex-
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Tab. I Metabolie excretion of porphyrins and their precursors in intermittent porphyria with normal porphobilinogen deaminase ac-
patients (.v, xmi„ — xmax* n = iyj sunenng rrom atuic uvujr »» u«v wtjruuvvj^.».
Excretion
Urinary
Faecal
Metabolites
5-aminolaevulinic acid [μιηοΙ/24 h]
porphobilinogen [μπιοΙ/24 h]
uropOφhyrin [nmol/24 h]
coproporphyrin [nmol/24 h]
total porphyrins0 [nmol/24 h]
coproporphyrin [nmol/g dry weight]
protoporphyrin [nmol/g dry weight]
total porphyrins6 [nmol/g dry weight]
Acute intermittent porphyria
Xmin
50
10
41
135
191
8
28
50
X
187
197
987
521
2348
24
93
120
Xma*
902
572
7399
2800
11449
60
199
311
Normal
xmi„
2
1
4
21
25
5
21
27
X
22
3
17
106
135
11
43
65
Xmax
49
8
29
119
165
37
151
224
a
 The difference between total porphyrins and the sum of uro- and
coproporphyrin is due to the presence of other porphyrins.
b
 The difference between total porphyrins and the sum of copro-
and protoporphyrin is due to the presence of other porphyrins.
hibited an activity within the overlapping range (72—
Acute intermittent porphyria patients with
normal porphobil inogen deaminase activity in
erythrocytes
Diagnosis of acute intermittent porphyria, with normal
porphobilinogen deaminase activity in the erythrocytes,
is based on the increased excretion of urinary 5-amino-
laevulinic acid and porphobilinogen as well as of por-
phyrins. Table 1 shows urinary and faecal excretion of
haem precursors in the group displaying normal enzyme
activity. Medians of urinary 5-aminolaevulinic acid and
porphobilinogen were enhanced 9- and 66-fold, respec-
tively, compared with the median of the control group.
The same is valid for urinary uroporphyrin, copropor-
phyrin and total porphyrins, which were elevated 58-, 5-
and 17-fold, respectively. The median of faecal porphy-
rins was within the normal range (see tab. 1).
Phases of acute intermittent porphyria with
normal porphobil inogen deaminase activity in
the erythrocytes
The patients with normal porphobilinogen deaminase
activity were investigated according to their excretion
levels of haem precursors and the occurrence of clinical
symptoms. This investigation showed a 3-, 9- and 26-
fold enhancement of urinary 5-aminolaevulinic acid in
the compensatory latent, the decompensatory latent (3)
and the acute phase, respectively, compared with the
median of the normal range. Urinary porphobilinogen
was enhanced 15-, 70- and 136-fold (fig. 1) and urinary
total porphyrins were increased 8-, 19- and 35-fold in
all three phases, respectively, compared with the median
of the normal range (fig. 2). However, in the compensa-
tory latent phase of the disease, urinary coproporphyrin
excretion is 6-fold higher than urinary uroporphyrin
excretion. In the decompensatory latent phase, the ratio
Uroporphyrin Coproporphyrin Total porphyrins
Fig. 2 Medians of urinary uroporphyrin, coproporphyrin and total
porphyrins of controls and acute intermittent porphyria patients
(n = 19) with normal porphobilinogen deaminase activity in the
erythrocytes.
Π normal (n = 20); H compensatory (n = 8);
Μ decompensatory (n = 7); H acute (n = 4).
of urinary uroporphyrin and coproporphyrin excretion is
1 : 1. In the acute phase of acute intermittent porphyria,
urinary uropoiphyrin excretion exceeds urinary copro-
porphyrin exretion 8-fold (fig. 2).
5-Aminolaevulinic acid Porphobilinogen
Fig. 1 Medians of urinary 5-aminolaevulinic acid and porphobili-
nogen of controls and acute intermittent porphyria patients
(n = 19) with normal porphobilinogen deaminase activity in the
erythrocytes.
D normal (n = 20); d compensatory (n = 8);
d decompensatory (n = 7); M acute (n = 4).
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Fig. 3 Relatives of an acute intermittent porphyria patient (family
Q) with normal porphobilinogen deaminase activity in the erythro-
cytes.
o D not tested; Φ 03 normal;
C B heterozygous deficient.
(The propositus is indicated by an arrow.)
Family studies
Three different families of acute intermittent porphyria
patients with normal porphobilinogen deaminase activ-
ity were further investigated. In family Qu (see fig. 3)
the acute intermittent porphyria patient (II/3, tab. 2)
excreted elevated amounts of urinary haem precursors.
The urinary excretions of 5-aminolaevulinic acid, por-
phobilinogen, uroporphyrin, coproporphyrin and total
porphyrins of her brother (II/2, tab. 2) were also en-
hanced. Another brother (II/l, tab. 2) and the nephew
(III/l, tab. 2) showed normal urinary excretion of haem
precursors (fig. 3).
Two daughters (family L, III/l and HI/2, tab. 3) of an
acute intermittent porphyria patient (II/l, tab. 3) with
normal porphobilinogen deaminase activity (108%)
were recognized as gene carriers of a porphobilinogen
deaminase defect by their enhanced urinary excretory
patterns of haem precursors. They exhibited different
porphobilinogen deaminase activities, which were 72
and 92% of the control level. The sister of this patient
(II/2, tab. 3) showed normal excretion of urinary haem
precursors (fig. 4, family L).
A third family (family F, fig. 5) was investigated. A
female (HI/4, tab. 4), suffering from acute intermittent
porphyria, excreted high amounts of urinary haem pre-
cursors. The grandmother (I/I), mother (II/3), the uncle
(II/2) and his wife (II/l) and three cousins (III/l, HI/2,
HI/3) showed normal urinary excretion of porphyrin pre-
cursors and porphyrins (see tab. 4). However, the grand-
mother was reported not to tolerate alcohol, and to pre-
sent with abdominal pain, vomiting and shortness of
breath. At the time of these symptoms, the urinary por-
phobilinogen and total porphyrins of the grandmother
were reported to be increased 88- and 29-fold, respec-
tively, compared with the median of the normal range.
The mother suffered from psychosis, abdominal colics,
nausea, muscular weakness and paresis of the legs. At
the time of these symptoms the urinary porphobilinogen
of the mother was elevated at 305 μιηοΙ/24 h.
A fourth family with acute intermittent porphyria and
normal porphobilinogen deaminase activity in the eryth-
rocytes was reported from the south of Germany. A fe-
male with urinary excretion of
5-aminolaevulinic acid
porphobilinogen
uroporphyrin
coproporphyrin
total porphyrins
= 165μιηο1/241ι,
= 213 μηιοΙ/14 h,
= 854nmol/24h,
= 981 nmol/24 h,
= 2515 nmol/24 h
and normal faecal porphyrins showed 97% porphobili-
nogen deaminase activity in the erythrocytes compared
with the control. Two brothers of this patient showed
elevated urinary haem precursors. Another brother and
the sister excreted normal amounts of urinary porphyrin
precursors and porphyrins. The siblings had 100 ± 5%
(x ± SD) porphobilinogen deaminase activity in the
erythrocytes compared with the control (K. Jacob, per-
sonal communication).
Course of acute in termit tent porphyria
in a female
The female acute intermittent porphyria patient (HI/4
fig. 5 and tab. 4) from family F with normal porphobili-
Tab. 2 Urinary excretion of haem precursors by family members
(family Qu) and a patient suffering from acute intermittent por-
phyria3 with normal porphobilinogen deaminase activity in the
erythrocytes. (Numbers of family members according to fig. 3).
Metabolites II/l II/2 II/3 III/l Normal
5-Aminolaevulinic acid [μηιοΙ/24 h]
Poφhobilinogen [μπκ>1/24 h]
Uroporphyrin [nmol/24 h]
Coproporphyrin [nmol/24 h]
Total porphyrinsb [nmol/24 h]
Porphobilinogen deaminase in erythrocytes
in % of controls
26
4
22
114
151
104
51
20
43
400
532
85
138
52
181
959
1421
88
8
2
10
75
94
100
< 49
< 8
< 29
<119
<165
85-110
a
 Faecal excretion: coproporphyrin = 10 nmol/g dry weight [(xy
n = 4); normal: 5—37 nmol/g dry weight], protoporphyrin: 75
nmol/g dry weight [(χ, η = 4); normal: 21-151 nmol/g dry
weight), total porphyrins = 102 nmol/g dry weight [(χ, η = 4); nor-
mal: 27-224 nmol/g dry weight].
b
 The difference between total porphyrins and the sum of uro- and
coproporphyrin is due to the presence of other porphyrins.
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Tab. 3 Urinary excretion of hacm precursors by family members
(family L) and patients suffering from acute intermittent por-
phyria0 with normal porphobilinogen deaminase activity in the
erythrocytes. (Numbers of family members according to fig. 4).
Metabolites
5-Aminolaevulinic acid [μηιοΙ/24 h]
Porphobi Imogen [μιηοΙ/24 h]
Uroporphyrin [nmol/24 h]
Coproporphyrin [nmol/24 h]
Total poiphyrinsb [nmol/24 h]
Porphobilinogen deaminase in
erythrocytes in % of controls
II/l
318
245
4069
339
4783 ·
108
II/2
29
5
16
112
154
104
III/l
50
12
4L
135
211
92
III/2
67
68
108
612
1197
72'
Normal
< 49
< 8
< 29
<119
<165
85-110
a
 Faecal excretion: coproporphyrin = 33 nmol/g dry weight [(*,
n = 4); normal: 5-37 nmol/g dry weight], protoporphyrin = 131
nmol/g dry weight [(,ν, n = 4); normal: 21-151 nmol/g dry
weight), total porphyrins = 164 nmol/g dry weight [(Λ-, η = 4); nor-
mal: 27-224 nmol/g dry weight].
b
 The difference between total porphyrins and the sum of uro- and
coproporphyrin is due to the presence of other porphyrins.
nogen deaminase activity was 20 years old and had a
six year history of her disease. She suffered from abdo-
minal pain, nausea, and vomiting over 5 years and un-
derwent a laparoscopy because cancer of the adnexes
was suspected. No pathological findings were revealed
in the uterus, adnexes and appendix, but she had re-
peated, convulsive abdominal pain, due to the applica-
tion of barbiturates for narcosis. An electro-encephalo-
gram was interpreted as indicative of epilepsy. Thus she
was treated with carbamazepin (2 X 200 mg per day),
Fig. 4 Relatives of an acute intermittent porphyria patient (family
L) with normal porphobilinogen deaminase activity in the erythro-
cytes.
o D not tested; 0m normal;
€ D heterozygous deficient.
(The propositus is indicated by an arrow.)
CMP, Φ
Fig. 5 Relatives of an acute intermittent porphyria patient (family
F) with normal porphobilinogen deaminase activity in the erythro-
cytes.
o D not tested; φ CD normal;
€ D heterozygous deficient. € suspected to be deficient.
(The propositus is indicated by an arrow.)
and her state of health worsened. She exhibited pain in
the legs and arms, abdominal colics, muscular weakness
and dizziness. Urinary haem precursors were analysed
(see day 0, tab. 5). Urinary 5-aminolaevulinic acid and
poiphobilinogen were elevated 41- and 99-fold, respec-
tively, while urinary uroporphyrin, coproporphyrin, and
total porphyrins were enhanced 214-, 16- and 43-fold,
respectively, compared with the median of the normal
range. At day 16, high doses of glucose (400 g per day)
were applied for three days, and carbamazepin was
omitted gradually. At day 18, 22 and 39 haem precursors
were decreased by 18-85%, 33-80% and 65-93%,
respectively, compared with day 0 (see tab. 5) and the
patient was free of symptoms after this period.
Discussion
The housekeeping and erythroid form of porphobilino-
gen deaminase are encoded by a single gene with two
different promoters (9). It produces two different
mRNAs with two, tissue-specific isoenzymes (10, 11).
Recently the human hepatic isoform of the enzyme has
been purified to homogeneity (12). In a Finnish family
with acute intermittent porphyria and normal porphobili-
nogen deaminase activity, a mutation exists in which the
enzyme defect is restricted to non-erythroid cells. Tran-
scription of the porphobilinogen deaminase gene in ery-
throid cells starts 2800 bases downstream from this mu-
tation. For that reason the mutation has no consequence
for the expression of the porphobilinogen deaminase
gene in erythrocytes (10). Some reported cases of acute
intermittent porphyria with normal erythroid activity,
but half the normal activity of the housekeeping isoen-
zyme, are the result of two mutations of the exon I/
intron 1 boundary. These mutations alter the splicing of
the hepatic specific transcript (1). We expect similar
mechanisms for our acute intermittent porphyria patients
with normal porphobilinogen deaminase activity in the
erythrocytes.
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Tab. 4 Urinary excretion of haem precursors by family members
(family F) and a patient suffering from acute intermittent por-
phyria11 with normal porphobilinogen deaminase activity in the
erythrocytes. (Numbers of family members according to fig. 5).
Metabolites
5-Aminolaevulinic acid [μηιοΙ/24 h]
Porphobilinogen [μηιοΙ/24 h]
Uropoφhyrin [nmol/24 h]
Coproporphyrin [nmol/24 h]
Total porphyrinsb [nmol/24 h]
I/I
13
8
10
70
89
II/l
7
2
5
32
41
II/2
24
4
12
75
97
II/3
25
3
6
116
146
III/l
15
2
12
87
110
II 1/2
14
3
14
90
115
HI/3
14
2
12
93
117
HI/4
347
268
1880
966
3159
Normal
< 49
< 8
< 29
<119
<165
Porphobilinogen deaminase in erythrocytes
in % of controls
92 94 90 102 87 99 85 85-110
a
 Faecal excretion: coproporphyrin = 16 nmol/g dry weight [(jc,
n = 8); normal: 5-37 nmol/g dry weight], protoporphyin = 40
nmol/g dry weight [(*, n = 8); normal: 21 — 151 nmol/g dry
weight), total porphyrins = 67 nmol/g dry weight [(*, n = 8); nor-
mal: 27-224 nmol/g dry weight].
A variant of acute intermittent porphyria with normal
porphobilinogen deaminase activity in the erythrocytes
was first reported from Finland (5). The authors sug-
gested, on the basis of 5-aminolaevulinic acid loading
tests, that the enzyme defect might be restricted to the
liver in this group (6). This indicates that the enzyme in
erythrocytes is not involved in the pathobiochemistry of
acute intermittent porphyria in this group, and that the
housekeeping enzyme is concerned in the disease pro-
cess. Thus porphobilinogen deaminase is expressed dif-
ferently in bone marrow and liver. Regulatory mecha-
nisms leading to induction of 5-aminolaevulinate syn-
thase result in the metabolic and clinical expression of
acute intermittent porphyria (3), both in patients with
decreased, and in those with normal porphobilinogen de-
aminase activity. Table 1 shows the urinary and faecal
excretion of haem precursors in our patients. Although
this kind of excretion is characteristic for acute intermit-
tent porphyria, the patients exhibit normal porphobilino-
gen deaminase activity in the erythrocytes. Therefore
this type of acute intermittent porphyria also exists in
Germany. An American case with acute intermittent por-
phyria and normal porphobiliniogen deaminase activity
has been identified (13). This subtype of acute intermit-
tent porphyria therefore exists in other populations.
Tab. 5 Urinary excretion of haem precursors by patient III/4
(family F) receiving glucose during the acute phase of acute in-
termittent porphyria with normal porphobilinogen deaminase activ-
ity in the erythrocytes, and with omission of carbamazepin.
Metabolites
5-Aminolaevulinic acid [μιηοΙ/24 h]
Porphobilinogen [μηιοΙ/24 h]
Uroporphyrin [nmol/24 h]
Coproporphyrin [nmol/24 h]
Total porphyrins* [nmol/24 h]
Day
0
902
297
3641
1667
5766
18
336
243
535
666
1333
22
313
198
723
350
1191
39
67
68
1266
467
1924
* The difference between total porphyrins and the sum of uro- and
coproporphyrin is due to the presence of other porphyrins.
b
 The difference between total porphyrins and the sum of uro- and
coproporphyrin is due to the presence of other porphyrins.
In Finland, the porphobilinogen deaminase mutations
with normal acitivty in the erythrocytes comprise 8% of
known porphobilinogen deaminase gene defects (14). In
our study 5% of the acute intermittent porphyria have
normal porphobilinogen deaminase activity in the eryth-
rocytes. Thus, in Finland and Germany, the frequency of
these mutations with normal porphobilinogen deaminase
activity is below 10%.
Acute intermittent porphyria can be classified into dif-
ferent types, according to the level of excretion of uri-
nary haem precursors and the occurrence of clinical
symptoms (3). These phases were also observed in acute
intermittent porphyria patients with normal porphobili-
nogen deaminase activity in the erythrocytes, as shown
in this paper. They are dependent on the degree of he-
patic disregulation of pyrrole-, porphyrin- and haem bio-
synthesis.
In table 2 the enhanced urinary excretion of haem pre-
cursors of person 11/2 and II/3 is shown. This indicates
the metabolic defect in the compensatory latent phase
of acute intermittent porphyria and characterizes these
persons as gene carriers.
In family L (tab. 3) the patient (II/l) and her two daugh-
ters (III/1, III/2) are shown to have the gene defect by
analyses of their urinary and faecal haem precursors.
The two daughters exhibited different porphobilinogen
deaminase activities in erythrocytes, one being normal
and one slightly lowered. There is no genetic reason for
this phenomenon. Exogenous influences may be respon-
sible, because the activity of porphobilinogen deaminase
is influenced by various factors, for example the age of
erythrocytes or haematological disorders with haemoly-
sis and increased erythropoiesis (6, 13). Other diseases,
which enhance or diminish porphobilinogen deaminase
activity, are chronic renal insufficiency, chronic poly-
arthritis and acute or chronic hepatic infections (15).
In family F (tab. 4) all individuals tested were normal
with respect to their exretion of urinary haem precursors,
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with the exception of the patient (HI/4). The grand-
mother and the mother were reported to have viscero-
neurological symptoms of acute intermittent porphyria.
These symptoms were dated to about 20 years ago in the
case of the mother and about 30 years ago in the case
of the grandmother. At the time of our investigations
these relatives were asymptomatic. In this context uri-
nary porphyrin precursors and porphyrin studies did not
show positive results. From a retrospective point of
view, a manifestation of porphyria years ago might have
been possible. This was confirmed by enhanced urinary
excretion of porphobilinogen and total poiphyrins at the
time of symptoms. In rare cases, urinary haem precur-
sors decrease to the normal range after an acute crisis
much earlier in the life of the patient.
In the case study, a female acute intermittent porphyria
patient with clinical exacerbation of the disease under
the influence of barbiturates and carbamazepin is de-
scribed. The diagnosis was established from the charac-
teristic elevated excretion of haem precursors, while
porphobilinogen deaminase activity was normal. Barbi-
turates and carbamazepin trigger acute intermittent por-
phyria by the induction of hepatic 5-aminolaevulinate
synthase (16, 17).
We conclude that the measurement of porphobilinogen
deaminase activity in the erythrocytes is not sufficient
for detecting gene carriers in families of acute intermit-
tent porphyria with this variant of normal enzyme activ-
ity. In such cases porphobilinogen deaminase mutation
analysis must be used. However, for this purpose the
specific mutation in the porphobilinogen deaminase
gene has to be identified (2). We are able to detect six
gene carriers in three acute intermittent porphyria fami-
lies with normal prophobilinogen deaminase activity by
using sensitive metabolite studies.
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